Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2017

01-06-2017 | NON-THEMATIC REVIEW

Cleavage and phosphorylation: important post-translational modifications of galectin-3

Authors: Xiaoge Gao, Jingjie Liu, Xiangye Liu, Liantao Li, Junnian Zheng

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Login to get access

Abstract

As the unique chimeric member of the β-galactoside-binding protein family, galectin-3 is a multivalent and multifunctional oncogenic protein involved in multiple physiological and pathological processes, including cell growth, cell differentiation, cell adhesion, RNA splicing, cell apoptosis, and malignant transformation. Post-translational modifications can effectively increase a protein’s functional diversity, either by degradation or adding chemical modifications, thus regulating activity, localization, and ligand interaction. In order to clearly understand the functional mechanisms of galectin-3 involved in normal cell biology and pathogenesis, here, we have summarized the previously reported post-translational modifications of galectin-3, including cleavage and phosphorylation. Cleavage of galectin-3 by MMPs, PSA, and proteases from parasites generated intact carbohydrate-recognition domain and N-terminal peptides of varying lengths that retained lectin binding activity but lost multivalence. Serine and tyrosine phosphorylation of galectin-3 by c-Abl, CKI, and GSK-3β could regulate its localization and associated signal transduction. Accordingly, cleavage and phosphorylation play an important role in regulating galectin-3 function via altering its multivalence, localization, and ligand interaction.
Literature
1.
Leffler, H., Carlsson, S., Hedlund, M., Qian, Y., & Poirier, F. (2004). Introduction to galectins. Glycoconjugate Journal, 19, 433–440.CrossRef
2.
Yang, R. Y., Rabinovich, G. A., & Liu, F. T. (2008). Galectins: Structure, function and therapeutic potential. Expert Reviews in Molecular Medicine, 10, e17.CrossRefPubMed
3.
Dumic, J., Dabelic, S., & Flögel, M. (2006). Galectin-3: An open-ended story. Biochimica et Biophysica Acta - General Subjects, 1760, 616–635.CrossRef
4.
Huflejt, M. E., Turck, C. W., Lindstedt, R., Barondes, S. H., & Leffler, H. (1993). L-29, a soluble lactose-binding lectin, is phosphorylated on serine 6 and serine 12 in vivo and by casein kinase I. Journal of Biological Chemistry, 268, 26712–26718.PubMed
5.
Gao, X., Liu, D., Fan, Y., Li, X., Xue, H., Ma, Y., Zhou, Y., & Tai, G. (2012). The two Endocytic pathways mediated by the carbohydrate recognition domain and regulated by the collagen-like domain of galectin-3 in vascular endothelial cells. PloS One, 7, e52430.CrossRefPubMedPubMedCentral
6.
Ochieng, J., Furtak, V., & Lukyanov, P. (2002). Extracellular functions of galectin-3. Glycoconjugate Journal, 19, 527–535.CrossRefPubMed
7.
Menon, R. P., & Hughes, R. C. (1999). Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. European Journal of Biochemistry, 264, 569–576.CrossRefPubMed
8.
Zhu, W. Q., & Ochieng, J. (2001). Rapid release of intracellular galectin-3 from breast carcinoma cells by fetuin. Cancer Research, 61, 1869–1873.PubMed
9.
Ahmad, N., Gabius, H. J., Andre, S., Kaltner, H., Sabesan, S., Roy, R., Liu, B. C., Macaluso, F., & Brewer, C. F. (2004). Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. Journal of Biological Chemistry, 279, 10841–10847.CrossRefPubMed
10.
Lepur, A., Salomonsson, E., Nilsson, U. J., & Leffler, H. (2012). Ligand induced galectin-3 protein self-association. Journal of Biological Chemistry, 287, 21751–21756.CrossRefPubMedPubMedCentral
11.
Shimura, T., Takenaka, Y., Tsutsumi, S., Hogan, V., Kikuchi, A., & Raz, A. (2004). Galectin-3, a novel binding partner of beta-catenin. Cancer Research, 64, 6363–6367.CrossRefPubMed
12.
Akahani, S., Nangia-Makker, P., Inohara, H., Kim, H. R. C., & Raz, A. (1997). Galectin-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Research, 57, 5272–5276.PubMed
13.
Shalom-Feuerstein, R., Plowman, S. J., Rotblat, B., Ariotti, N., Tian, T., Hancock, J. F., & Kloog, Y. (2008). K-Ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Research, 68, 6608–6616.CrossRefPubMedPubMedCentral
14.
Liu, F. T., Patterson, R. J., & Wang, J. L. (2002). Intracellular functions of galectins. Biochimica et Biophysica Acta - General Subjects, 1572, 263–273.CrossRef
15.
Jensen, O. N. (2004). Modification-specific proteomics: Characterization of post-translational modifications by mass spectrometry. Current Opinion in Chemical Biology, 8, 33–41.CrossRefPubMed
16.
17.
Rundhaug, J. E. (2003). Matrix Metalloproteinases, angiogenesis, and cancer. Clinical Cancer Research, 9, 551.PubMed
18.
Lynch, C. C., & Matrisian, L. M. (2002). Matrix metalloproteinases in tumor-host cell communication. Differentiation, 70, 561–573.CrossRefPubMed
19.
Nagase, H., Visse, R., & Murphy, G. (2006). Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research, 69, 562.CrossRefPubMed
20.
Ochieng, J., Fridman, R., Nangia-Makker, P., Kleiner, D. E., Liotta, L. A., Stetler-Stevenson, W. G., & Raz, A. (1994). Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry, 33, 14109–14114.CrossRefPubMed
21.
Ochieng, J., Green, B., Evans, S., James, O., & Warfield, P. (1998). Modulation of the biological functions of galectin-3 by matrix metalloproteinases. Biochimica et Biophysica Acta - General Subjects, 1379, 97–106.CrossRef
22.
Nangia-Makker, P., Raz, T., Tait, L., Hogan, V., Fridman, R., & Raz, A. (2007). Galectin-3 cleavage: A novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Research, 67, 11760–11768.CrossRefPubMedPubMedCentral
23.
Balan, V., Nangia-Makker, P., Schwartz, A. G., Young, S. J., Tait, L., Hogan, V., Raz, T., Wang, Y., Zeng, Q. Y., Gen, S. W., Guo, Y., Li, H., Abrams, J., Couch, F. J., Lingle, W. L., Lloyd, R. V., Ethier, S. P., Tainsky, M. A., & Raz, A. (2008). Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): A pilot study. Cancer Research, 68, 10045–10050.CrossRefPubMedPubMedCentral
24.
Nangia-Makker, P., Wang, Y., Raz, T., Tait, L., Balan, V., Hogan, V., & Raz, A. (2010). Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. International Journal of Cancer. Journal International du Cancer, 127, 2530–2541.CrossRefPubMedPubMedCentral
25.
Ortega, N., Behonick, D. J., Colnot, C., Cooper, D. N. W., & Werb, Z. (2005). Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during Endochondral bone formation. Molecular Biology of the Cell, 16, 3028–3039.CrossRefPubMedPubMedCentral
26.
Dange, M. C., Agarwal, A. K., & Kalraiya, R. D. (2015). Extracellular galectin-3 induces MMP9 expression by activating p38 MAPK pathway via lysosome-associated membrane protein-1 (LAMP1). Molecular and Cellular Biochemistry, 404, 79–86.CrossRefPubMed
27.
Wang, Y. G., Kim, S. J., Baek, J. H., Lee, H. W., Jeong, S. Y., & Chun, K. H. (2012). Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Experimental & Molecular Medicine, 44, 387–393.CrossRef
28.
Mauris, J., Woodward, A. M., Cao, Z., Panjwani, N., & Argueso, P. (2014). Molecular basis for MMP9 induction and disruption of epithelial cell–cell contacts by galectin-3. Journal of Cell Science, 127, 3141–3148.CrossRefPubMedPubMedCentral
29.
Puthenedam, M., Wu, F., Shetye, A., Michaels, A., Rhee, K. J., & Kwon, J. H. (2011). Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells. Inflammatory Bowel Diseases, 17, 260–267.CrossRefPubMed
30.
McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., Fridman, R., & Rempel, S. A. (2007). SPARC Upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG Glioma cells. Neuroscience Letters, 419, 172–177.CrossRefPubMedPubMedCentral
31.
Guevremont, M., Martel-Pelletier, J., Boileau, C., Liu, F., Richard, M., Fernandes, J., Pelletier, J., & Reboul, P. (2004). Galectin-3 surface expression on human adult chondrocytes: A potential substrate for collagenase-3. Annals of the Rheumatic Diseases, 63, 636–643.CrossRefPubMedPubMedCentral
32.
Yokoyama, Y., Grunebach, F., Schmidt, S. M., Heine, A., Hantschel, M., Stevanovic, S., Rammensee, H. G., & Brossart, P. (2008). Matrilysin (MMP-7) is a novel broadly expressed tumor antigen recognized by antigen-specific T cells. Clinical Cancer Research, 14, 5503–5511.CrossRefPubMed
33.
Itoh, Y., & Seiki, M. (2006). MT1-MMP: A potent modifier of pericellular microenvironment. Journal of Cellular Physiology, 206, 1–8.CrossRefPubMed
34.
Jones, J. L., Saraswati, S., Block, A. S., Lichti, C. F., Mahadevan, M., & Diekman, A. B. (2010). Galectin-3 is associated with Prostasomes in human semen. Glycoconjugate Journal, 27, 227–236.CrossRefPubMed
35.
36.
Saraswati, S., Block, A. S., Davidson, M. K., Rank, R. G., Mahadevan, M., & Diekman, A. B. (2011). Galectin-3 is a substrate for prostate specific antigen (PSA) in human seminal plasma. The Prostate, 71, 197–208.CrossRefPubMedPubMedCentral
37.
Balan, V., Wang, Y., Nangia-Makker, P., Kho, D., Bajaj, M., Smith, D., Heilbrun, L., Raz, A., & Heath, E. (2013). Galectin-3: A possible complementary marker to the PSA blood test. Oncotarget, 4, 542–549.CrossRefPubMedPubMedCentral
38.
Rabinovich, G. A., Baum, L. G., Tinari, N., Paganelli, R., Natoli, C., Liu, F. T., & Iacobelli, S. (2002). Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends in Immunology, 23, 313–320.CrossRefPubMed
39.
Hsu, D. K., Chen, H. Y., & Liu, F. T. (2009). Galectin-3 regulates T-cell functions. Immunological Reviews, 230, 114–127.CrossRefPubMed
40.
Debierre-Grockiego, F., Niehus, S., Coddeville, B., Elass, E., Poirier, F., Weingart, R., Schmidt, R. R., Mazurier, J., Guerardel, Y., & Schwarz, R. T. (2010). Binding of toxoplasma gondii glycosylphosphatidylinositols to galectin-3 is required for their recognition by macrophages. Journal of Biological Chemistry, 285, 32744–32750.CrossRefPubMedPubMedCentral
41.
Van Den Berg, T. K., Honing, H., Franke, N., Van Remoortere, A., Schiphorst, W. E. C. M., Liu, F. T., Deelder, A. M., Cummings, R. D., Hokke, C. H., & Van Die, I. (2004). LacdiNAc-glycans constitute a parasite pattern for galectin-3-mediated immune recognition. Journal of Immunology, 173, 1902–1907.CrossRef
42.
Pelletier, I., & Sato, S. (2002). Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope. The Journal of Biological Chemistry, 277, 17663–17670.CrossRefPubMed
43.
Yamazaki, K., Kawai, A., Kawaguchi, M., Hibino, Y., Li, F., Sasahara, M., Tsukada, K., & Hiraga, K. (2001). Simultaneous induction of galectin-3 phosphorylated on tyrosine residue, p21WAF1/Cip1/Sdi1, and the proliferating cell nuclear antigen at a distinctive period of repair of hepatocytes injured by CCl4. Biochemical and Biophysical Research Communications, 280, 1077–1084.CrossRefPubMed
44.
Menon, S., Kang, C. M., & Beningo, K. A. (2011). Galectin-3 secretion and tyrosine phosphorylation is dependent on the calpain small subunit, Calpain 4. Biochemical and Biophysical Research Communications, 410, 91–96.CrossRefPubMedPubMedCentral
45.
Balan, V., Nangia-Makker Pratima, P., Jung, Y. S., Wang, Y., & Raz, A. (2010). Galectin-3: A novel substrate for c-Abl kinase. Biochimica et Biophysica Acta - Molecular Cell Research, 1803, 1198–1205.CrossRef
46.
Shaul, Y. (2000). C-Abl: Activation and nuclear targets. Cell Death and Differentiation, 7, 10–16.CrossRefPubMed
47.
Li, X., Ma, Q., Wang, J., Liu, X., Yang, Y., Zhao, H., Wang, Y., Jin, Y., Zeng, J., Li, J., Song, L., Li, P., Qian, X., & Cao, C. (2010). C-Abl and Arg tyrosine kinases regulate lysosomal degradation of the oncoprotein galectin-3. Cell Death and Differentiation, 17, 1277–1287.CrossRefPubMed
48.
Mayer, B. J., & Baltimore, D. (1993). Signalling through SH2 and SH3 domains. Trends in Cell Biology, 3, 8–13.CrossRefPubMed
49.
Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., & Pawson, T. (1991). SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins. Science, 252, 668–674.CrossRefPubMed
50.
Knippschild, U., Gocht, A., Wolff, S., Huber, N., Lohler, J., & Stoter, M. (2005). The casein kinase 1 family: Participation in multiple cellular processes in eukaryotes. Cellular Signalling, 17, 675–689.CrossRefPubMed
51.
Agrwal, N., Cowles, E. A., Anderson, R. L., & Wang, J. L. (1990). Carbohydrate-binding protein 35: Isoelectric points of the polypeptide and a phosphorylated derivative. The Journal of Biological Chemistry, 265, 17706–17712.PubMed
52.
Mazurek, N., Conklin, J., Byrd, J. C., Raz, A., & Bresalier, R. S. (2000). Phosphorylation of the beta-galactoside-binding protein galectin-3 modulates binding to its ligands. Journal of Biological Chemistry, 275, 36311–36315.CrossRefPubMed
53.
Yoshii, T., Fukumori, T., Honjo, Y., Inohara, H., Kim, H. R. C., & Raz, A. (2002). Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. Journal of Biological Chemistry, 277, 6852–6857.CrossRefPubMed
54.
55.
Kim, H. R., Lin, H. M., Biliran, H., & Raz, A. (1999). Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Research, 59, 4148–4154.PubMed
56.
Takenaka, Y., Fukumori, T., Yoshii, T., Oka, N., Inohara, H., Hyeong-Reh, C. K., Bresalier, R. S., & Raz, A. (2004). Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Molecular and Cellular Biology, 24, 4395–4406.CrossRefPubMedPubMedCentral
57.
Chiarugi, P., & Giannoni, E. (2008). Anoikis: A necessary death program for anchorage-dependent cells. Biochemical Pharmacology, 76, 1352–1364.CrossRefPubMed
58.
Lee, Y. J., Song, Y. K., Song, J. J., Siervo-Sassi, R. R., Kim, H. R., Li, L., Spitz, D. R., Lokshin, A., & Kim, J. H. (2003). Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Experimental Cell Research, 288, 21–34.CrossRefPubMed
59.
Suliman, A., Lam, A., Datta, R., & Srivastava, R. K. (2001). Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene, 20, 2122–2133.CrossRefPubMed
60.
Mazurek, N., Yun, J. S., Liu, K. F., Gilcrease, M. Z., Schober, W., Nangia-Makker, P., Raz, A., & Bresalier, R. S. (2007). Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. Journal of Biological Chemistry, 282, 21337–21348.CrossRefPubMed
61.
Mazurek, N., Sun, Y. J., Price, J. E., Ramdas, L., Schober, W., Nangia-Makker, P., Byrd, J. C., Raz, A., & Bresalier, R. S. (2005). Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Research, 65, 10767–10775.CrossRefPubMed
62.
Díez-Revuelta, N., Velasco, S., André, S., Kaltner, H., Kübler, D., Gabius, H. J., & Abad-Rodríguez, J. (2010). Phosphorylation of adhesion- and growth-regulatory human galectin-3 leads to the induction of axonal branching by local membrane L1 and ERM redistribution. Journal of Cell Science, 123, 671–681.CrossRefPubMed
63.
Plyte, S. E., Hughes, K., Nikolakaki, E., Pulverer, B. J., & Woodgett, J. R. (1992). Glycogen synthase kinase-3: Functions in oncogenesis and development. Biochimica et Biophysica Acta - Reviews on Cancer, 1114, 147–162.CrossRef
64.
Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., & Kikuchi, A. (1998). Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. The EMBO Journal, 17, 1371–1384.CrossRefPubMedPubMedCentral
65.
Rao, T. P., & Kuhl, M. (2010). An updated overview on Wnt signaling pathways: A prelude for more. Circulation Research, 106, 1798–1806.CrossRefPubMed
66.
Shimura, T., Takenaka, Y., Fukumori, T., Tsutsumi, S., Okada, K., Hogan, V., Kikuchi, A., Kuwano, H., & Raz, A. (2005). Implication of galectin-3 in Wnt signaling. Cancer Research, 65, 3535–3537.CrossRefPubMed
67.
Song, S., Mazurek, N., Liu, C., Sun, Y., Ding, Q. Q., Liu, K., Hung, M. C., & Bresalier, R. S. (2009). Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Research, 69, 1343–1349.CrossRefPubMedPubMedCentral
68.
69.
Yu, L. G., Andrews, N., Zhao, Q., McKean, D., Williams, J. F., Connor, L. J., Gerasimenko, O. V., Hilkens, J., Hirabayashi, J., Kasai, K., & Rhodes, J. M. (2007). Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. Journal of Biological Chemistry, 282, 773–781.CrossRefPubMed
70.
Davidson, P. J., Davis, M. J., Patterson, R. J., Ripoche, M. A., Poirier, F., & Wang, J. L. (2002). Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology, 12, 329–337.CrossRefPubMed
71.
Fukumori, T., Takenaka, Y., Yoshii, T., Kim, H. R. C., Hogan, V., Inohara, H., Kagawa, S., & Raz, A. (2003). CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Research, 63, 8302–8311.PubMed
72.
Hunter, T. (1995). Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell, 80, 225–236.CrossRefPubMed
Metadata
Title
Cleavage and phosphorylation: important post-translational modifications of galectin-3
Authors
Xiaoge Gao
Jingjie Liu
Xiangye Liu
Liantao Li
Junnian Zheng
Publication date
01-06-2017
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9666-0

Other articles of this Issue 2/2017

Cancer and Metastasis Reviews 2/2017 Go to the issue

ReviewPaper

Platelet “first responders” in wound response, cancer, and metastasis

NON-THEMATIC REVIEW

Cytokine-induced senescence for cancer surveillance

ReviewPaper

Platelets, circulating tumor cells, and the circulome

CLINICAL

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

Announcement

Biography—David Menter

OriginalPaper

The influence of platelet membranes on tumour cell behaviour
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits